Evidence map›Paper›PMID 33529209›Full record

ArticlePLoS pathogens2021

Capsule carbohydrate structure determines virulence in Acinetobacter baumannii.

Yuli Talyansky, Travis B Nielsen, Jun Yan, Ulrike Carlino-Macdonald, Gisela Di Venanzio, Somnath Chakravorty, Amber Ulhaq, Mario F Feldman, Thomas A Russo, Evgeny Vinogradov and 4 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed.

  1. Article
  2. Article
  3. Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Membrane-Focused Strategies AgainstAntibiotics (Basel, Switzerland) · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Quorum sensing geneFrontiers in microbiology · 2026
    Article
  13. Review
  14. Article
  15. Article
  16. Carbapenem-ResistantMicroorganisms · 2025
    Review
  17. Microbiology spectrum · 2025
    Article
  18. Fast and accurateMicrobial genomics · 2025
    Article
  19. HypervirulentAntibiotics (Basel, Switzerland) · 2025
    Review
  20. Structure of K102 Capsular Polysaccharide fromInternational journal of molecular sciences · 2025
    Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuli TalyanskyDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, California, United States of America.ORCID 0000-0003-1899-3664
Travis B NielsenDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, California, United States of America.ORCID 0000-0003-3366-7912
Jun YanDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, California, United States of America.ORCID 0000-0001-7509-2067
Ulrike Carlino-MacdonaldDivision of Infectious Diseases, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Veterans Administration, Buffalo, New York, United States of America.ORCID 0000-0002-3460-7789
Gisela Di VenanzioDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America.ORCID 0000-0003-1969-3145
Somnath ChakravortyDivision of Infectious Diseases, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Veterans Administration, Buffalo, New York, United States of America.
Amber UlhaqDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, California, United States of America.ORCID 0000-0002-7781-469X
Mario F FeldmanDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America.ORCID 0000-0003-4497-0976
Thomas A RussoDivision of Infectious Diseases, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Veterans Administration, Buffalo, New York, United States of America.ORCID 0000-0003-4566-7442
Evgeny VinogradovNational Research Council Canada, Human Health Therapeutics Centre, Ottawa, Canada.ORCID 0000-0002-5364-1376
Brian LunaDepartment of Molecular Microbiology & Immunology, University of Southern California, Los Angeles, California, United States of America.ORCID 0000-0001-6718-4551
Meredith S WrightRady Children's Institute for Genomic Medicine, San Diego, California, United States of America.
Mark D AdamsThe Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America.ORCID 0000-0003-3161-7460
Brad SpellbergLAC+USC Medical Center, Los Angeles, California, United States of America.

Funding

MAb Passive Vaccination against Acinetobacter baumanniiR01AI130060 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRAD J SPELLBERG · 2017 to 2026
$6.7M
Humanized Monoclonal Antibody to Treat Acinetobacter InfectionsR42AI106375 · NIAID · BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC · PI ISLAM, KHALID · 2016 to 2018
$3.1M
Transferrin Combination Therapy to Address Antimicrobial ResistanceR01AI117211 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2016 to 2019
$2.7M
Characterization of Rifabutin Therapy Against Antibiotic-Resistant BacteriaR01AI139052 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LUNA, BRIAN MICHAEL · 2018 to 2021
$2.4M
INVESTIGATING TYPE VI SECRETION IN ACINETOBACTER BAUMANNII AND ITS INTERPLAY WITH ANTIBIOTIC RESISTAR01AI125363 · NIAID · WASHINGTON UNIVERSITY · PI FELDMAN, MARIO · 2016 to 2020
$1.9M
DHODH Inhibitors: A Potential New Class of Antimicrobials for Treatment of the Drug Resistant Gram-Negative Bacillus Acinetobacter baumanniiR56AI129986 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI PHILLIPS, MARGARET A., RUSSO, THOMAS A · 2018 to 2018
$982k
Humanized Monoclonal Antibodies to Treat Acinetobacter InfectionsR41AI106375 · NIAID · BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC · PI SPELLBERG, BRAD J · 2013 to 2014
$574k
Transferrin As a Novel Approach to Combat MucormycosisR21AI132923 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2018 to 2019
$454k
Determining the value of PBP 7/8 as an antimicrobial target for XDR-A. baumannniiI01BX004677 · VA · VA WESTERN NEW YORK HEALTHCARE SYSTEM · PI THOMAS A RUSSO · 2020 to 2026
–
BLRD VA I01 BX004677NIAID NIH HHS R01 AI117211NIAID NIH HHS R01 AI125363NIAID NIH HHS R01 AI130060NIAID NIH HHS R01 AI139052NIAID NIH HHS R21 AI132923NIAID NIH HHS R41 AI106375NIAID NIH HHS R42 AI106375NIAID NIH HHS R56 AI129986
6 · The paper itself

Abstract

Acinetobacter baumannii is a highly antibiotic-resistant bacterial pathogen for which novel therapeutic approaches are needed. Unfortunately, the drivers of virulence in A. baumannii remain uncertain. By comparing genomes among a panel of A. baumannii strains we identified a specific gene variation in the capsule locus that correlated with altered virulence. While less virulent strains possessed the intact gene gtr6, a hypervirulent clinical isolate contained a spontaneous transposon insertion in the same gene, resulting in the loss of a branchpoint in capsular carbohydrate structure. By constructing isogenic gtr6 mutants, we confirmed that gtr6-disrupted strains were protected from phagocytosis in vitro and displayed higher bacterial burden and lethality in vivo. Gtr6+ strains were phagocytized more readily and caused lower bacterial burden and no clinical illness in vivo. We found that the CR3 receptor mediated phagocytosis of gtr6+, but not gtr6-, strains in a complement-dependent manner. Furthermore, hypovirulent gtr6+ strains demonstrated increased virulence in vivo when CR3 function was abrogated. In summary, loss-of-function in a single capsule assembly gene dramatically altered virulence by inhibiting complement deposition and recognition by phagocytes across multiple A. baumannii strains. Thus, capsular structure can determine virulence among A. baumannii strains by altering bacterial interactions with host complement-mediated opsonophagocytosis.

Indexed as

PhagocytosisVirulenceAcinetobacter baumanniiAcinetobacter InfectionsAnimalsBacterial CapsulesMaleMiceMice, Inbred C3HMice, Inbred C57BLPhagocytesPolysaccharides, BacterialRAW 264.7 CellsPolysaccharides, Bacterial

Identifiers

PMID33529209
PMCPMC7880449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.